… how and when lipoprotein(a) [Lp(a)] is tested and clinically evaluated in lipid clinics
throughout Europe, and the challenges that may prevent evaluation from being carried out. …

… Lipoprotein(a) (Lp(a)) is a low density lipoprotein-like particle in which apolipoprotein B100
is covalently linked to the unique apolipoprotein(a). There is a mounting body of evidence …

… Outcomes (AIM-HIGH) 40 RCT evaluated the hypothesis that increasing HDL-C (and
improving other lipid/lipoprotein end points) would confer significantly enhanced cardioprotective …

… that more attention should be paid to the management of the causal factor responsible for …
Furthermore, given that the Veterans Affairs High Density Lipoprotein Intervention Trial9 has …

… Each of these arguments and alternative approaches to the clinical evaluation of LDL can …
ATP III represents a major increment in the management of lipids and lipoproteins to prevent …

… understand how and when lipoprotein(a) [Lp(a)] is tested and clinically evaluated in lipid
clinics throughout Europe, and the challenges that may prevent evaluation from being carried …

… that intervention is as effective in preventing recurrent myocardial infarction and mortality
in patients experiencing a recurrent attack as it is in primary prevention. The complete set of …

… Although few studies have evaluated this lipoprotein ratio for predicting cardiovascular
disease, and as it is a lineal combination of the results can be assumed to be similar to those of …

… In the evaluation and treatment of patients with lipoprotein abnormalities, are there … to
prevent, halt, or reverse atherosclerosis, it is important to identify which lipoproteins, or lipoprotein …

… Research Evaluation (AGREE) instrument was used for the evaluation and inclusion of the
… -density lipoprotein cholesterol (LDLC) was the most important lipid fraction in the prevention …